1. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
- Author
-
Dinicola S, Chiu TT, Unfer V, Carlomagno G, and Bizzarri M
- Subjects
- Androgens blood, Animals, Drug Therapy, Combination, Female, Humans, Inositol administration & dosage, Inositol chemistry, Insulin Resistance, Oocytes metabolism, Polycystic Ovary Syndrome physiopathology, Stereoisomerism, Vitamin B Complex administration & dosage, Vitamin B Complex chemistry, Inositol therapeutic use, Polycystic Ovary Syndrome drug therapy, Vitamin B Complex therapeutic use
- Abstract
PCOS is one of the most common endocrine disorders affecting women and it is characterized by a combination of hyper-androgenism, chronic anovulation, and insulin resistance. While a significant progress has recently been made in the diagnosis for PCOS, the optimal infertility treatment remains to be determined. Two inositol isomers, myo-inositol (MI) and D-chiro-inositol (DCI) have been proven to be effective in PCOS treatment, by improving insulin resistance, serum androgen levels and many features of the metabolic syndrome. However, DCI alone, mostly when it is administered at high dosage, negatively affects oocyte quality, whereas the association MI/DCI, in a combination reproducing the plasma physiological ratio (40:1), represents a promising alternative in achieving better clinical results, by counteracting PCOS at both systemic and ovary level., (© 2014, The American College of Clinical Pharmacology.)
- Published
- 2014
- Full Text
- View/download PDF